Meet The Professors - Lung 1

Meet The Professors: A case-based discussion on the management of lung cancer in the adjuvant, locally advanced and metastatic settings

OVERVIEW OF ACTIVITY

Lung cancer is the leading cause of cancer mortality in the United States in both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85 percent of patients who develop lung cancer will die from it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on patient outcomes, but with the advent of biologic agents, recent improvements have been seen in time to progression and survival in lung cancer clinical trials. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with experts’ perspectives, this CME program is designed to assist medical oncologists with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.

LEARNING OBJECTIVES

Evaluate the clinical implications of emerging research findings in lung cancer treatment, and incorporate these data into management strategies in the adjuvant, neoadjuvant, locally advanced and metastatic settings.
Recognize the unique challenges that accompany the therapeutic management of lung cancer in patients of advanced age, compromised performance status and/or extensive comorbidity.
Assess the impact of histology, gender, EGFR testing (IHC, FISH, mutation analyses) and smoking history in the selection of treatment for patients with non-small cell lung cancer (NSCLC).
Formulate individualized treatment plans addressing the first-line and subsequent management of recurrent or progressive NSCLC, considering unique patient and tumor characteristics.
Compare and contrast the efficacy and toxicity profiles of bevacizumab and cetuximab when selecting a front-line chemobiologic regimen for patients with metastatic NSCLC.
Critically evaluate the current role (on and off protocol) and scientific rationale for the integration of biologic agents into the multimodality treatment of locally advanced Stage III NSCLC.
Counsel appropriately selected patients with lung cancer about the availability of ongoing clinical trials.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the audio and complete the Educational Assessment and Credit Form located in our website at ResearchToPractice.com/MTP/Lung.

This program is supported by educational grants from Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology/OSI Oncology and ImClone Systems Incorporated.